Analyst Rating Update on Novartis AG (NVS)

Novartis AG (NYSE:NVS) : The consensus on Novartis AG (NYSE:NVS) based on 10 analyst recommendation on the company stock is 2.53, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 2 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Novartis AG (NYSE:NVS) : Average target price received by Novartis AG (NYSE:NVS) is $92.75 with an expected standard deviation of $15.2. The most aggressive target on the stock is $115, whereas the most downbeat target is $81. 4 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy. Also, Morgan Stanley downgrades their rating on the shares of Novartis AG (NYSE:NVS). The current rating of the shares is Underperform. Earlier, the shares were rated a Equal-weight by the brokerage firm. The rating by the firm was issued on April 12, 2016.

Novartis AG (NYSE:NVS): stock turned positive on Tuesday. Though the stock opened at $78.72, the bulls momentum made the stock top out at $79.63 level for the day. The stock recorded a low of $78.5 and closed the trading day at $79.59, in the green by 3.04%. The total traded volume for the day was 1,622,246. The stock had closed at $77.24 in the previous days trading.

Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.